UPDATE: Jefferies Lowers PT on Abbott Laboratories as Top US Pharma Pick
June 07, 2013 at 12:24 PM EDT
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT ), but lowered the price target from $46.00 to $44.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014
